A Phase II / III, prospective, randomised, active-controlled, open label, Parallel group, 2-arm, Multi-centric trial for evaluation of Efficacy, Safety, and Tolerability of DTaP plus Hib (Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b) combination vaccine in Indian paediatric population in comparison with Pentaxim® (Diphtheria, acellular Pertussis, Tetanus, Hemophilus influenza b and IPV) combination vaccine of Sanofi Pasteur

Trial Profile

A Phase II / III, prospective, randomised, active-controlled, open label, Parallel group, 2-arm, Multi-centric trial for evaluation of Efficacy, Safety, and Tolerability of DTaP plus Hib (Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b) combination vaccine in Indian paediatric population in comparison with Pentaxim® (Diphtheria, acellular Pertussis, Tetanus, Hemophilus influenza b and IPV) combination vaccine of Sanofi Pasteur

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs DTP-Haemophilus-influenza-B-vaccine-Wockhardt (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Wockhardt Ltd
  • Most Recent Events

    • 05 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top